Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C32H43ClN2O2S |
| Molecular Weight | 555.214 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCC(=O)OCCN1CCN(CC\C=C2/C3=C(SC4=C2C=C(Cl)C=C4)C=CC=C3)CC1
InChI
InChIKey=QRUAPADZILXULG-UVHMKAGCSA-N
InChI=1S/C32H43ClN2O2S/c1-2-3-4-5-6-7-8-15-32(36)37-24-23-35-21-19-34(20-22-35)18-11-13-27-28-12-9-10-14-30(28)38-31-17-16-26(33)25-29(27)31/h9-10,12-14,16-17,25H,2-8,11,15,18-24H2,1H3/b27-13+
| Molecular Formula | C32H43ClN2O2S |
| Molecular Weight | 555.214 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987
Curator's Comment: Description was created based on several sources, including
https://www.lundbeck.com/upload/au/files/pdf/Clopixol_CMI.pdf | https://www.ncbi.nlm.nih.gov/pubmed/26624987
Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and
dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2
receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 |
|||
Target ID: CHEMBL2056 |
|||
Target ID: CHEMBL2094251 |
|||
Target ID: CHEMBL2093870 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CLOPIXOL Approved UseZuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. |
|||
| Primary | CLOPIXOL Approved UseZuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The bucco-linguo-masticatory syndrome as a side-effect of neuroleptics therapy. | 1967 |
|
| The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. | 1986 Dec |
|
| Prolonged oculogyric crisis on addition of nifedipine to neuroleptic medication regime. | 1987 Jan |
|
| Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study. | 1987 Jul |
|
| Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. | 1991 Dec |
|
| [acute dystonias in combined abuse of cocaine and neuroleptics]. | 1994 Nov 26 |
|
| Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs. | 2001 Jul |
|
| Clozapine and weight gain. | 2001 May |
|
| Pro-oxidant activity of zuclopenthixol in vivo: differential effect of the drug on brain oxidative status of scopolamine-treated rats. | 2004 Aug |
|
| Long term results of unilateral posteroventral pallidotomy for antipsychotic drug induced tardive dyskinesia. | 2005 Jul |
|
| Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. | 2009 Nov 13 |
|
| Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. | 2010 Apr |
|
| Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. | 2012 Apr 18 |
|
| Simultaneous determination of 25 common pharmaceuticals in whole blood using ultra-performance liquid chromatography-tandem mass spectrometry. | 2012 Sep |
|
| Paradoxical severe agitation induced by add-on high-doses quetiapine in schizo-affective disorder. | 2014 May 15 |
Patents
Sample Use Guides
Clopixol tablets: The usual dose is 10 to 50 mg per
day.
Clopixol Acuphase injection: The usual dose is 50 to 150 mg (1 to 3 mL) every 2 to 3 days or as
instructed by your doctor.
Clopixol Depot injection: The usual dose is 200 to 400 mg (1 to 2 mL) every second to fourth week.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:38:13 GMT 2023
by
admin
on
Fri Dec 15 20:38:13 GMT 2023
|
| Record UNII |
WBS0PLG8GD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6450313
Created by
admin on Fri Dec 15 20:38:13 GMT 2023 , Edited by admin on Fri Dec 15 20:38:13 GMT 2023
|
PRIMARY | |||
|
WBS0PLG8GD
Created by
admin on Fri Dec 15 20:38:13 GMT 2023 , Edited by admin on Fri Dec 15 20:38:13 GMT 2023
|
PRIMARY |